Genentech's Hedgehog inhibitor could be filed by year end
This article was originally published in Scrip
Executive Summary
A pivotal Phase II study of Genentech's Hedgehog Pathway Inhibitor vismodegib (GDC-0449) has met its primary endpoint and showed positive results in people with advanced basal cell carcinoma (BCC), a severe type of skin cancer, said the Roche subsidiary. Genentech is developing vismodegib under a collaboration agreement with Curis.